Who is sponsoring NCT00513058?

NCT00513058 is sponsored by UNICANCER.

What condition does NCT00513058 study?

NCT00513058 studies Breast Cancer.

What drugs are being tested in NCT00513058?

Interventions: Lapatinib, vinorelbine.

What is the status of NCT00513058?

NCT00513058 is currently COMPLETED.

Last reviewed 2014-01-13 · How we verify

Phase I Study Evaluating the Combination of Lapatinib + Vinorelbine in Patients With Locally Advanced or Metastatic Breast Cancer Overexpressing HER2

NCT00513058 Phase 1 COMPLETED

RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with vinorelbine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and vinorelbine in treating women with HER2-overexpressing locally advanced or metastatic breast cancer.

Details

Lead sponsor	UNICANCER
Phase	Phase 1
Status	COMPLETED
Enrolment	33
Start date	2007-06
Completion	2012-04

Conditions

Breast Cancer

Interventions

Lapatinib
vinorelbine

Primary outcomes

Toxicity as assessed by NCI CTCAE v3.0 — during the first cycle of treatment

Countries

France